Study Examines Insulin Therapies

AUGUST 01, 2004

Data from the INITIATE (INITiation of Insulin to reach A1c TargEt) study revealed that Novo Nordisk's NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection [rDNA origin]), a dual-action insulin analog without neutral protamine Hagedorn, showed improved blood glucose lowering in patients with type 2 diabetes. The researchers found that NovoLog Mix 70/30 is more effective in helping patients who are starting insulin therapy to achieve control of their blood glucose levels, compared with insulin glargine.

The study examined insulin-na ïve patients whose blood glucose levels were not being controlled with oral diabetes medications (A1c levels >8%). After 28 weeks, 66% of patients taking NovoLog Mix 70/30 achieved levels of 7%, compared with 40% in the insulin glargine group. In fact, 42% of patients taking NovoLog Mix 70/30 reached an A1c of ≤6.5%, compared with 28% taking glargine. (The findings were presented at the annual meeting of the American Diabetes Association.)



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.